Table 1 Demographic and clinical characteristics of subjects with ADHD
| Â | ADHD (n = 112) | Responders (n = 62) | Non-responders (n = 50) | p-value |
|---|---|---|---|---|
Age in yr, mean (SD) | 9.1 (2.1) | 9.1 (2.0) | 9.0 (2.2) | 0.79 |
Sex (M/F) | 92/20 | 54/8 | 38/12 | 0.13 |
IQ, mean (SD) | 107.4 (13.7) | 107.8 (13.2) | 106.9 (14.4) | 0.73 |
ADHD subtypes | Â | Â | Â | 0.30 |
   Combined | 61.6% | 58.1% | 66.0% |  |
   Inattentive | 25.9% | 25.8% | 26.0% |  |
   Hyperactive-impulsive | 5.4% | 4.8% | 6.0% |  |
   NOS | 7.1% | 11.3% | 2.0% |  |
Comorbidity | Â | Â | Â | Â |
   Oppositional defiant disorder | 13.4% | 8.0% | 20.0% | 0.07 |
   Anxiety disorder | 10.7% | 9.7% | 12.0% | 0.69 |
   Enuresis | 4.5% | 6.5% | 2.0% | 0.26 |
ARS baseline scores, mean (SD) | Â | Â | Â | Â |
   Total | 26.9 (10.3) | 25.9 (11.1) | 28.3 (8.8) | 0.23 |
   Inattentive | 15.1 (5.8) | 14.2 (5.9) | 16.3 (5.6) | 0.07 |
   Hyperactivity/impulsivity | 11.8 (6.0) | 11.6 (6.3) | 12.0 (5.7) | 0.75 |
Dosage of MPH (mg/day), mean (SD) | Â | Â | Â | Â |
   Baseline dose | 19.9 (8.3) | 18.6 (6.2) | 21.5 (10.1) | 0.08 |
   Final 2 weeks dose | 29.2 (11.6) | 28.2 (10.9) | 30.4 (12.4) | 0.32 |